Form 4: 10x Genomics CFO Receives Significant RSU Grant

10x Genomics' Chief Financial Officer, Adam Taich, was granted 106,579 Restricted Stock Units, signaling long-term executive alignment.

Summary

• Adam Taich, Chief Financial Officer of 10x Genomics, Inc. (TXG), acquired 106,579 shares of Class A Common Stock.
• The acquisition was in the form of Restricted Stock Units (RSUs) with a stated price of $0 per unit.
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• The RSUs will vest quarterly, with 1/12th vesting on each quarterly anniversary measured from February 21, 2026.
• Vesting is contingent upon Mr. Taich continuing as a service provider through each vesting date.
• Following this transaction, Mr. Taich beneficially owns 394,996 shares of Class A Common Stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive event. While it represents standard executive compensation and potential future dilution, it also signals management's long-term commitment and alignment with shareholder interests through equity ownership.

Positives

• The grant of Restricted Stock Units (RSUs) to the Chief Financial Officer aligns executive incentives with long-term shareholder value.
• The significant number of units (106,579) indicates a substantial commitment to retaining key management personnel.
• The vesting schedule over three years encourages sustained performance and stability in leadership.

Negatives

• The issuance of new shares upon vesting of RSUs will result in a degree of share dilution for existing shareholders over time.

Risks

• The vesting of the Restricted Stock Units is subject to the Reporting Person continuing as a service provider through each vesting date, meaning forfeiture could occur if employment ceases.

Future Outlook

The long-term vesting schedule for the granted Restricted Stock Units suggests an expectation of continued service from the Chief Financial Officer and a strategic alignment with the company's future performance over the next three years.

Industry Context

StockSavvy.ai notes that granting Restricted Stock Units (RSUs) is a common practice in the biotechnology and life sciences industry for executive compensation. This method helps retain key talent by tying a significant portion of their compensation to the company's stock performance and their continued employment, which is particularly relevant in a sector reliant on long-term research and development cycles.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a standard practice across the technology and life sciences sectors, comparable to compensation structures at companies like Illumina or Pacific Biosciences.
• The multi-year vesting schedule (quarterly over three years) is typical for executive equity grants, designed to promote long-term retention and align executive interests with shareholder value, similar to programs seen at peer companies.

Stakeholder Impact

• Shareholders: Potential future dilution as RSUs vest and convert to common stock, but also benefit from increased executive alignment with long-term company performance.
• Employees: May view this as a positive sign of executive commitment and stability within the company.
• Management (Adam Taich): Receives significant long-term equity compensation, incentivizing continued service and performance.

Next Steps

• The Restricted Stock Units will begin vesting on a quarterly basis, starting from the first quarterly anniversary of February 21, 2026, subject to the CFO's continued service.

Key Dates

Keywords

10x Genomics, TXG, Adam Taich, CFO, Restricted Stock Units, RSU grant, insider transaction, executive compensation, Form 4, equity compensation